Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes

Jorge E. Cortes, Hagop Kantarjian, Susan O'Brien, Michael Keating, Sherry Pierce, Emil J. Freireich, Elihu Estey

Research output: Contribution to journalArticle

Abstract

Trisomy 21 is the second most common trisomy in patients with acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). However, its clinical and prognostic significance is not known. We analyzed the records of 1187 consecutive patients with untreated AML or MDS. Thirty-seven (3.3%) had trisomy 21: four (0.3%) as the only cytogenetic abnormality and 33 (2.7%) with other cytogenetic abnormalities (-5 and/or -7 in 15, +8 in nine, t(15;17) in three, inv(18) in three, t(8;21) in one, and hyperdiploid with several other additional chromosomes in two). Twenty-eight patients had AML and nine MDS. No patients had megakaryocytic phenotype (M7), common in patients with constitutional trisomy 21 (Down's syndrome) and AML. Overall, 57% achieved complete remission (CR), with median CR duration of 39 weeks, and median survival of 31 weeks. When patients with additional cytogenetic abnormalities were compared to patients with similar abnormalities but no trisomy 21, their clinical features as well as their CR rate, CR duration and survival were similar, with or without trisomy 21. We conclude that trisomy 21 in AML typically presents in conjunction with other cytogenetic abnormalities, especially -5/-7 and +8 whose presence rather than the presence of +21 dictates the clinical outcome.

Original languageEnglish (US)
Pages (from-to)115-117
Number of pages3
JournalLeukemia
Volume9
Issue number1
StatePublished - Jan 1995
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Down Syndrome
Acute Myeloid Leukemia
Chromosome Aberrations
Polyploidy
Survival
Trisomy
Chromosomes
Phenotype

Keywords

  • AML
  • Myelodysplasia
  • Trisomy 21

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Cortes, J. E., Kantarjian, H., O'Brien, S., Keating, M., Pierce, S., Freireich, E. J., & Estey, E. (1995). Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes. Leukemia, 9(1), 115-117.

Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes. / Cortes, Jorge E.; Kantarjian, Hagop; O'Brien, Susan; Keating, Michael; Pierce, Sherry; Freireich, Emil J.; Estey, Elihu.

In: Leukemia, Vol. 9, No. 1, 01.1995, p. 115-117.

Research output: Contribution to journalArticle

Cortes, JE, Kantarjian, H, O'Brien, S, Keating, M, Pierce, S, Freireich, EJ & Estey, E 1995, 'Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes', Leukemia, vol. 9, no. 1, pp. 115-117.
Cortes, Jorge E. ; Kantarjian, Hagop ; O'Brien, Susan ; Keating, Michael ; Pierce, Sherry ; Freireich, Emil J. ; Estey, Elihu. / Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes. In: Leukemia. 1995 ; Vol. 9, No. 1. pp. 115-117.
@article{a78ef253651c4c489c2fd0bcac932718,
title = "Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes",
abstract = "Trisomy 21 is the second most common trisomy in patients with acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). However, its clinical and prognostic significance is not known. We analyzed the records of 1187 consecutive patients with untreated AML or MDS. Thirty-seven (3.3{\%}) had trisomy 21: four (0.3{\%}) as the only cytogenetic abnormality and 33 (2.7{\%}) with other cytogenetic abnormalities (-5 and/or -7 in 15, +8 in nine, t(15;17) in three, inv(18) in three, t(8;21) in one, and hyperdiploid with several other additional chromosomes in two). Twenty-eight patients had AML and nine MDS. No patients had megakaryocytic phenotype (M7), common in patients with constitutional trisomy 21 (Down's syndrome) and AML. Overall, 57{\%} achieved complete remission (CR), with median CR duration of 39 weeks, and median survival of 31 weeks. When patients with additional cytogenetic abnormalities were compared to patients with similar abnormalities but no trisomy 21, their clinical features as well as their CR rate, CR duration and survival were similar, with or without trisomy 21. We conclude that trisomy 21 in AML typically presents in conjunction with other cytogenetic abnormalities, especially -5/-7 and +8 whose presence rather than the presence of +21 dictates the clinical outcome.",
keywords = "AML, Myelodysplasia, Trisomy 21",
author = "Cortes, {Jorge E.} and Hagop Kantarjian and Susan O'Brien and Michael Keating and Sherry Pierce and Freireich, {Emil J.} and Elihu Estey",
year = "1995",
month = "1",
language = "English (US)",
volume = "9",
pages = "115--117",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes

AU - Cortes, Jorge E.

AU - Kantarjian, Hagop

AU - O'Brien, Susan

AU - Keating, Michael

AU - Pierce, Sherry

AU - Freireich, Emil J.

AU - Estey, Elihu

PY - 1995/1

Y1 - 1995/1

N2 - Trisomy 21 is the second most common trisomy in patients with acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). However, its clinical and prognostic significance is not known. We analyzed the records of 1187 consecutive patients with untreated AML or MDS. Thirty-seven (3.3%) had trisomy 21: four (0.3%) as the only cytogenetic abnormality and 33 (2.7%) with other cytogenetic abnormalities (-5 and/or -7 in 15, +8 in nine, t(15;17) in three, inv(18) in three, t(8;21) in one, and hyperdiploid with several other additional chromosomes in two). Twenty-eight patients had AML and nine MDS. No patients had megakaryocytic phenotype (M7), common in patients with constitutional trisomy 21 (Down's syndrome) and AML. Overall, 57% achieved complete remission (CR), with median CR duration of 39 weeks, and median survival of 31 weeks. When patients with additional cytogenetic abnormalities were compared to patients with similar abnormalities but no trisomy 21, their clinical features as well as their CR rate, CR duration and survival were similar, with or without trisomy 21. We conclude that trisomy 21 in AML typically presents in conjunction with other cytogenetic abnormalities, especially -5/-7 and +8 whose presence rather than the presence of +21 dictates the clinical outcome.

AB - Trisomy 21 is the second most common trisomy in patients with acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). However, its clinical and prognostic significance is not known. We analyzed the records of 1187 consecutive patients with untreated AML or MDS. Thirty-seven (3.3%) had trisomy 21: four (0.3%) as the only cytogenetic abnormality and 33 (2.7%) with other cytogenetic abnormalities (-5 and/or -7 in 15, +8 in nine, t(15;17) in three, inv(18) in three, t(8;21) in one, and hyperdiploid with several other additional chromosomes in two). Twenty-eight patients had AML and nine MDS. No patients had megakaryocytic phenotype (M7), common in patients with constitutional trisomy 21 (Down's syndrome) and AML. Overall, 57% achieved complete remission (CR), with median CR duration of 39 weeks, and median survival of 31 weeks. When patients with additional cytogenetic abnormalities were compared to patients with similar abnormalities but no trisomy 21, their clinical features as well as their CR rate, CR duration and survival were similar, with or without trisomy 21. We conclude that trisomy 21 in AML typically presents in conjunction with other cytogenetic abnormalities, especially -5/-7 and +8 whose presence rather than the presence of +21 dictates the clinical outcome.

KW - AML

KW - Myelodysplasia

KW - Trisomy 21

UR - http://www.scopus.com/inward/record.url?scp=0028910557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028910557&partnerID=8YFLogxK

M3 - Article

C2 - 7845005

AN - SCOPUS:0028910557

VL - 9

SP - 115

EP - 117

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 1

ER -